An Introduction to the Psychedelic Renaissance
40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health and wellbeing crisis.
After decades of repression, psychedelic research is thriving.
Decriminalisation and legalisation campaigns are succeeding.
In 2020 the U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with many other states and localities poised to follow suit. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.
Significant clinical trial milestones on the horizon.
In a Phase 3 MDMA-assisted therapy for PTSD trial that published last year, 88% of participants responded to the treatment. The trial’s sponsor, MAPS, expects to seek FDA approval in or around 2024. Multiple trials of psilocybin for depression are in Phase 2 or entering Phase 3, and are indicating preliminary safety and efficacy.
Psychedelics have the potential to address depression anxiety addiction PTSD chronic pain
Welcome to the Psychedelic Renaissance.
Our most popular psychedelic sector resources.
The Psychedelic Renaissance in Context
Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.
The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.
Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.
mid 1960s – 1971
Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.
Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.
1950s and ’60s
Fertile decades for psychedelics research and experimentation, particularly in the U.S.
Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.
Our Latest Analysis
Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round
This week: MAPS PBC finished its second Phase 3 trial of MDMA-AT for PTSD; we contextualise atai’s upcoming PCN-101 (R-Ketamine) readout; Tactogen launches crowdfunding round; and much more…
Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A
This week: Colorado’s Prop 122 passes, decriminalising a number of psychedelics and establishing regulated psilocybin therapy; many Oregon counties opt-out; Sensorium closes $30m Series A round; and much more…
Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM
This week: we take a look at the newest 5-MeO-DMT company to emerge; COMPASS’ Phase 2b psilocybin trial published in NEJM; Apex Labs set to trial take-home psilocybin; and much more…
Receive Our Updates
Join our Newsletter
Psychedelic insights, commentary and analysis delivered to your inbox, including our weekly Bulletin.
Follow Us on Twitter
Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.